Egetis Therapeutics (EGTX) Q2 2026: FDA Review of Emcitate® NDA on Track for September 28 PDUFA Date Amid 23% European Sales Growth

Egetis Therapeutics (EGTX) Q2 2026: FDA Review of Emcitate® NDA on Track for September 28 PDUFA Date Amid 23% European Sales Growth →

Egetis Therapeutics AB, the orphan drug specialist listed on Nasdaq Stockholm and developer of Emcitate® (tiratricol) for MCT8 deficiency, released its Q2 2026 interim results on 21 August 2026. The company confirmed the FDA's review of its…